ArticleCureus2026
Time to Relapse Following Rituximab Therapy in Rheumatoid Arthritis and Its Determinants: A Single-Center Observational Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRituximab (RTX), a monoclonal antibody targeting CD20, is effective in rheumatoid arthritis (RA) refractory to conventional and biological disease-modifying antirheumatic drugs (DMARDs). However, treatment response is not always sustained, and relapse may occur after variable intervals. Time to relapse (TTR) represents the duration during which RTX maintains clinical and biological efficacy before disease recurrence.
objectivesThis study aimed to evaluate TTR after the most recent RTX cycle in patients with RA and to identify the clinical, biological, and therapeutic factors associated with its duration.
methodsWe conducted a retro-prospective, single-center observational study including patients with RA treated with RTX between 2021 and 2025. The primary outcome was physician-assessed objective TTR following the most recent RTX cycle. Relapse-free survival was estimated using Kaplan-Meier analysis. Univariable and multivariable linear regression analyses were performed to identify clinical, biological, and treatment-related factors associated with TTR. Patient-reported relapse was collected as a secondary outcome and analyzed separately to allow comparison with physician-assessed relapse timing.
resultsA total of 97 patients were included, of whom 84 (84/97, 86.6%) were female. The mean age was 57 ± 10 years, and the median disease duration was 16 years (interquartile range (IQR) 10-22). RTX was administered as retreatment in 75 patients (75/97, 77.3%) and as first-line biologic therapy in 22 patients (22/97, 22.7%). The median objective TTR was nine months (IQR 7-11), which was similar to the patient-reported TTR of 9 months (IQR 6-11). One-year flare-free survival was observed in 36 patients (36/97, 37.1%). In univariable analysis, lower baseline swollen joint count (SJC) and erythrocyte sedimentation rate (ESR) were associated with longer TTR. In multivariable analysis, only SJC remained independently associated with TTR (
conclusionsThe median TTR following RTX therapy in RA was approximately nine months. Baseline inflammatory burden, particularly SJC, emerged as the main factor associated with relapse timing, whereas RTX dose and number of treatment cycles were not significantly associated with TTR. These findings suggest that disease activity at the time of RTX administration may influence subsequent relapse timing. However, given the observational design and modest predictive performance of the final model, prospective studies are needed to confirm these observations and determine their implications for individualized retreatment strategies in RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.